New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For HITK;AEZS;AMED;IMGN;HTWR;CRVL;SQNM;MDAS;DSCI;CCRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
07:00 EDTHTWRHeartWare reports Q3 EPS (64c), consensus (65c)
Subscribe for More Information
October 29, 2014
16:23 EDTMDASMedAssets sees FY14 adjusted EPS $1.34-$1.38, consensus $1.35
Sees FY14 revenue $715M-$721M, consensus $703.88M. Prior views were $1.32-$1.40 for EPS and $698M-$710M for revenue.
16:21 EDTMDASMedAssets reports Q3 adjusted EBTIDA $59.5M, up 10.3%
16:20 EDTMDASMedAssets reports Q3 adjusted EPS 34c, consensus 31c
Reports Q3 revenue $175.7M, consensus $172.51M.
11:56 EDTAMEDAmedisys upgraded to Neutral from Underperform at RW Baird
Subscribe for More Information
07:05 EDTAMEDAmedisys reports Q3 EPS 26c, consensus 15c
Reports Q3 revenue $300.28M, consensus $299.26M.
October 28, 2014
11:14 EDTIMGNRoche unit announces collaboration pact with ImmunoGen
Ventana Medical Systems, a member of the Roche Group (RHHBY), announced it has entered into an agreement with ImmunoGen (IMGN) to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry test for one or more of ImmunoGen's product candidates. Under this agreement, the companies have created an initial test for folate receptor alpha, or FRa, that is being used in early trials of IMGN853, ImmunoGen's FRa-targeting antibody-drug conjugate.
October 27, 2014
07:34 EDTAEZSAeterna Zentaris implements U.S. sales force to sell ASCEND's Estrogel
Subscribe for More Information
October 24, 2014
06:31 EDTIMGNImmunoGen backs FY15 revenue $100M-$105M, consensus $101.12M
Subscribe for More Information
06:31 EDTIMGNImmunoGen reports Q1 EPS (26c), consensus (15c)
Subscribe for More Information
October 23, 2014
15:39 EDTIMGNNotable companies reporting before tomorrow's open
Subscribe for More Information
October 21, 2014
15:00 EDTHTWRUpdate suggests HeartWare CE mark trial on track, says Wells Fargo
Wells Fargo said the clinicaltrials.gov posting for HeartWare's MVAD CE Mark trial, which had not been changed since April 2013, was updated on October 16 and now indicates the trial is scheduled to start in April 2015. Wells expects HeartWare to update on MVAD on its Q3 call next week, but the firm said that it does not expect any major surprises based on the updated posting. Wells Fargo maintains its Market Perform rating on HeartWare.
07:54 EDTIMGNLeerink a buyer of Alkermes, ImmunoGen, Incyte
Subscribe for More Information
October 20, 2014
07:19 EDTIMGNIBC Life Sciences to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use